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Innate  Defense  Regulators  (IDRs)  are  short  synthetic  peptides  that  target  the  host innate  immune  system
via  an  intracellular  adaptor  protein  which  functions  at key  signaling  nodes.  In this  work,  further  details
of the  mechanism  of action  of  IDRs  have  been  discovered.
The  studies  reported  here show  that the  lead  clinical  IDR,  SGX94,  has broad-spectrum  activity  against
Gram-negative  and Gram-positive  bacterial  infections  caused  by  intracellular  or extracellular  bacteria
and  also  complements  the  actions  of standard  of care  antibiotics.  Based  on  in  vivo  and  primary  cell  cul-
ture  studies,  this  activity  is shown  to  result  from  the  primary  action  of SGX94  on tissue-resident  cells  and
subsequent  secondary  signaling  to activate  myeloid-derived  cells,  resulting  in  enhanced  bacterial  clear-
ance and  increased  survival.  Data  from  non-clinical  and clinical  studies  also  show  that  SGX94  treatment
modulates  pro-inﬂammatory  and  anti-inﬂammatory  cytokine  levels,  thereby  mitigating  the  deleterious
inﬂammatory  consequences  of  innate  immune  activation.  Since  they  act through  host  pathways  to pro-road spectrum
hemical compounds studied in this article:
ancomycin (PubChem CID: 14969)
oxycycline (PubChem CID: 54671203)
efepime (PubChem CID: 9571075)
vide both  broad-spectrum  anti-infective  capability  as well  as  control  of  inﬂammation,  IDRs  are  unlikely
to  be impacted  by  resistance  mechanisms  and  offer potential  clinical  advantages  in the ﬁght  against
emerging  and  antibiotic  resistant  bacterial  infections.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).usquetide (PubChem CID: 71722017)
. Introduction
Innate immunity, with its dual impact on inﬂammation and
nfection, plays a signiﬁcant role in many acute and chronic dis-
ases, ranging from the bacterial, fungal and viral infections, to the
nﬂammatory consequences of gastrointestinal disease (Elia et al.,
016) and to the less intuitive host inﬂammatory disorders such
s oral mucositis (Sonis, 2010). Although the infection-clearing
nd inﬂammatory pathways of the innate immune system have
een shown to be separable (Foster et al., 2007; Mehta and Jeffrey,
015), successful therapeutic treatments directed at the innate
Abbreviations: IDR, innate Defense Regulator; MAD, multiple ascending dose
tudy; SAD, single ascending dose study.
∗ Corresponding author.
E-mail address: odonini@soligenix.com (O. Donini).
ttp://dx.doi.org/10.1016/j.jbiotec.2016.03.032
168-1656/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uimmune system must balance the impact on these pathways. Ther-
apies focused on innate immunity have primarily targeted either
the inputs (e.g., toll-like receptor (TLR) agonists and antagonists
(Lin et al., 2009)) or outputs (e.g., TNF, IL-1 receptor antago-
nists) of the innate immune system. Such therapies dramatically
bias the system towards either increased prophylactic infection-
clearing action combined with (potentially harmful) inﬂammation
or towards decreased inﬂammation with the side effect of increased
susceptibility to infection.
The Innate Defense Regulators (IDRs) now offer an alternative
approach to infectious diseases and other disorders by targeting
a key integrating checkpoint in intracellular innate immune path-
ways, with the potential to separately modulate infection-clearing
and inﬂammatory pathways to both decrease inﬂammation and
increase infection-clearing responses (Scott et al., 2007; Yu et al.,
2009). IDRs are a new class of short, synthetic peptides that were
previously shown to interact directly with sequestosome-1 (sqstm;
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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lso known as p62) (Yu et al., 2009; Supplementary Fig. S1), which
s known to function downstream of the TLRs and other innate
mmune receptors (Into et al., 2010; Park et al., 2013; Kim and
zato, 2009; van der Vaart et al., 2014). p62 is an ancient protein,
resent in all mammals and highly conserved across species with
1% sequence identity between mouse and man  and 99% between
rangutan and man.
Innate defenses involve numerous cell types distributed
hroughout the body both in circulation and in tissue-resident com-
artments and are active at all environmental anatomical barriers
Janeway and Medzhitov, 2002). Given the evolving understand-
ng of the complexity of innate immune interactions and immune
urveillance at various anatomical locations, we have chosen to
ursue a reductionist approach in the exploration of IDR function.
hus, we initially characterized IDR action in a variety of in vivo
odels, followed by in vitro and ex vivo evaluations. As previously
eported for IDR-1 (Scott et al., 2007), and shown here for a clinical
ompound from the IDR class (SGX94), the IDRs improve outcome
n murine models of both local and systemic infections with a broad
rray of bacterial pathogens whether administered prophylacti-
ally or therapeutically and either as a stand-alone agent or in
onjunction with suboptimal antibiotic treatment. Simultaneously
he IDRs mitigate deleterious inﬂammatory consequences of innate
mmune activation. The clinical compound, SGX94, is an analog
f IDR-1, speciﬁcally designed to have more drug-like properties,
ncluding a lower net charge (and therefore decreased potential for
ystemic toxicity), smaller size (and therefore lower cost of goods),
mproved chemical stability and marginally improved biological
tability.
Here we report non-clinical and clinical studies indicating that
he therapeutic effects of SGX94 depend upon tissue-resident
nnate immune cells, an under-appreciated therapeutic target in
he innate immune system. The data show that IDRs interact pri-
arily with tissue resident cells that use myeloid derived cells
including macrophages) as secondary messengers, resulting in
nhanced clearance of bacteria and increased survival after acute
acterial infection.
.1. Materials and methods
.1.1. Peptides and endotoxin
SGX94 peptide (acetate salt, USAN: dusquetide) and triﬂuo-
oacetic acid (TFA) salts of analog peptides were synthesized by
olid phase synthesis (CS-Bio Peptide Synthesizer, Model #CS136)
sing standard ﬂuorenylmethoxycarbonyl (FMOC) chemistry pro-
ocols (Scott et al., 2007) and puriﬁed by cold ether precipitation.
uriﬁed peptides were analyzed by high performance liquid chro-
atography (HPLC; Agilent Model 1100). Peptide purity was
ypically greater than 95%. All IDR peptides were formulated in
queous solution for intravenous (IV) administration. LPS was  pur-
hased commercially (Escherichia coli 0111:b4 LPS).
.2. Cytokine/chemokine analysis
Chemokine and cytokine concentrations in mouse peritoneal
avage samples were determined using ELISA kits according to the
anufacturer’s instructions. ELISA kits for mouse RANTES (CCL5),
P-10 (CXCL10), KC and MIP-1 were purchased from R&D Sys-
ems; mouse IL-6 and TNF- ELISA kits were purchased from BD
iosciences. Mouse TNF-, IL-1, and IL-6 levels in bronchiolar
avage ﬂuid were measured using Luminex technology (Progenics)
nd IL-1ra levels were measured using an ELISA kit (R&D Systems).Cytokine levels present in mouse cell culture supernatants were
xamined using Meso Scale Discovery (MSD®) Cytokine Assays
ith the SECTOR® Imager 2400 (MSD®). Data were analyzed using
SD® DISCOVERY WORKBENCH software (version 3.0.18). Forhnology 226 (2016) 24–34 25
some experiments, IL-10 was measured by ELISA (R&D Systems),
according to the manufacturer’s instructions.
IL-1ra levels in the monkey plasma samples were quantiﬁed
using an ELISA kit (Catalog No. DRA00B, R&D Systems). This human
IL-1ra ELISA kit has been shown previously to be useful in quan-
tiﬁcation of monkey IL-1ra (Reyes and Coe, 1998; Xiao et al.,
1999). Human cytokines and chemokines were quantiﬁed by Rules
Based Medicine, Inc. utilizing their standard protocols (https://rbm.
myriad.com/).
1.3. Differential cell counting
Cytospin slides were prepared by depositing cells from peri-
toneal lavage ﬂuid onto microscope slides using a cytofuge (Stat
Spin CytoFuge). Cells were then ﬁxed and stained with Hemacolor
regular stain set and visualized under a microscope. Macrophages
and neutrophils were identiﬁed and counted in 3 different views,
from which average values for each sample were determined.
1.4. Monocyte-macrophage differentiation in vitro:
Puriﬁed human peripheral blood mononuclear cells (PBMCs)
were sourced from Stem Cell Technologies. Macrophage differ-
entiation was induced by culturing the CD14+ monocytes with
recombinant human GM-CSF (10 ng/mL, rhGM-CSF, R&D Systems)
according to the protocol of Verreck et al. (2004). In short, mono-
cytes were incubated for approximately 5 days in RPMI 1640
(ATCC) containing 10% heat-inactivated fetal bovine serum (FBSi)
(FBS, Hyclone), 100 U/mL penicillin (Sigma-Aldrich), 100 g/mL
streptomycin (Sigma-Aldrich), 2 mM l-glutamine (Sigma-Aldrich),
and GM-CSF. The effect of SGX94 on monocyte to macrophage
differentiation was  examined by pre-treating the monocytes
with SGX94 (200 M)  for 30 min  (min) prior to addition of
growth factor. To determine the effect of pre-incubation with
SGX94 on the differentiated macrophage phenotype, differentiated
macrophages were then stimulated with various concentrations of
LPS (10–1000 ng/mL) for 20 h and culture supernatants were ana-
lyzed for cytokines and chemokines.
1.5. Splenocyte supernatant transfer studies
The impact of SGX94 and peptide analogs on soluble factors
released by mouse splenocytes was  studied using in vitro super-
natant transfer experiments. Spleen cells were isolated from 6
to 10 week old female C57BL/6 or BALB/c mice by digestion
of spleens for 30 min  at 37 ◦C after injection of 0.13 Wünsch
units/spleen of Liberase TM (Roche) in RPMI (ATCC) contain-
ing 10% Fetal Bovine Serum (FBS, Hyclone), 100 U/mL penicillin,
100 g/mL streptomycin and 50 M 2-mercaptoethanol (com-
plete RPMI). Splenocytes in complete RPMI medium were cultured
at 4 × 106 cells/mL in 24 well plates for 24 h after addition of
100 ng/mL LPS and 200 M SGX94. Over the same 24 h period,
mouse macrophages were cultured for 24 h in DMEM (ATCC) con-
taining 10% FBS. Splenocyte supernatants were centrifuged and
diluted to 20% in DMEM (ATCC) containing 10% FBS. The RAW264.7
culture medium was  then aspirated and replaced with splenocyte-
conditioned supernatants. After a further 24 h culture, TNF, IL-6
and IL-10 cytokine levels were measured in the RAW264.7 culture
supernatants.
1.6. Animal modelsAll experimental procedures using animals were carried out in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
2 Biotec
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ealth and performed in IACUC-approved research facilities with
he approval of the facility’s Animal Care and Use Committee.
.6.1. Pharmacokinetic (PK) studies in mice and cynomolgus
onkeys
Blood samples were collected from mice administered 20, 60 or
0 mg/kg SGX94 daily over 14 days (3 mice/sex/group/time point)
n Day 14 at 3, 15, 30 min, 1, 2, 3, 6, and 24 h post-dose. Follow-
ng IV injection, plasma concentrations of SGX94 declined very
apidly in a multi-exponential manner in both sexes. Relatively high
lasma clearance (∼3 to 5 mL/min/kg) and very short mean resi-
ence time (MRT) ranging from 2 to 6 min  was noted (Table 1). This
uggested that no signiﬁcant accumulation was occurring upon
ultiple daily dosing. The PK proﬁle was also characterized in
ynomolgus monkeys that had received 20, 80 or 160 mg/kg SGX94
aily for 14 days by slow (2–3 min) IV injection (3M + 3F per dose
evel). Blood samples (approximately 1 mL  each) were collected
n Day 14 at: pre-dose, 0.05, 0.25, 0.5, 1, 2, 3, 6 and 24 h after
GX94 injection. K3EDTA plasma was prepared and SGX94 concen-
rations were determined by LC–MS/MS using validated methods
quantitation limit 0.1 ng/mL). PK analysis was performed using
on-compartmental methods.
.6.2. Quantitative whole body autoradiography (QWBA)
An IV bolus dose of 20 mg/kg [14C]SGX94 was administered to
ale CD-1 mice (n = 6) and animals were euthanized at 2, 5, 15,
0, 60 and 240 min  post-dose. Each carcass was frozen, embedded,
ectioned, and mounted for QWBA. Selected sections were exposed
o phosphor image screens and tissue radioactivity concentrations
ere quantiﬁed from the whole-body autoradiograms using a val-
dated image analysis system. An additional 3 animals received
0 mg/kg [14C]SGX94 and were euthanized at 5 min  post-dose to
ssess the metabolite distribution in blood.
.6.3. Staphylococcus aureus peritoneal infections in mice
Six to 8 week old female CD-1 mice were infected by intraperi-
oneal (IP) injection with 6 × 107 colony forming units (CFU) S.
ureus (Catalog No. 25923, ATCC) in 5% mucin. Control (saline) or
GX94 (TFA form; dissolved in sterile saline; 9.5 mg/kg) was admin-
stered IP 4 h after the infection. At 24 h after infection, mice were
acriﬁced and peritoneal lavage was performed by injecting 5 mL  of
BS into the peritoneal cavity and withdrawing the lavage ﬂuid. For
numeration of CFU in the peritoneal lavage ﬂuid, diluted lavage
uid was plated on Mueller Hinton agar plates and incubated at
7 ◦C for 24 h. Bacterial colonies were then counted and the CFU/mL
as calculated for each sample.
.6.4. MRSA peritoneal infections in mice
SGX94 or saline was administered IV to 4 week old female CF-1
ice at 50 mg/kg 48 h prior to bacterial infection (n = 10 per group).
ice were infected IP with 8.2 × 107 CFU of MRSA UC6685. Van-
omycin was administered twice subcutaneously (SC) at 3 mg/kg, 1
nd 5 h after bacterial infection. Survival was monitored once daily
or 5 days.
.6.5. MRSA bacteremia in mice
Female, BALB/c mice, 7–8 weeks old, were challenged IV with
RSA strain USA300 (1.1–2 × 107CFU). Linezolid was prepared for
ral dosing in an aqueous dosing vehicle of 0.5% methylcellulose
nd 5% PEG200. Five separate experiments have been completed
ith this model using BALB/c mice and one with nu/nu mice, uti-
izing a range of SGX94 (IV) and linezolid (oral) dosing schedules.
epresentative results are shown in Figs. 1 d,h and 2 a–c . The pri-
ary endpoint used to assess progress of the infection and drug
ctivity was bacteremia-mediated death. Deaths were recorded up
o 21 days. Animals were observed at least twice daily during thehnology 226 (2016) 24–34
study period for signs of mortality and morbidity. Kaplan-Meier
survival plots were prepared for the resulting data using GraphPad
Prism v.4.0.
1.6.6. MRSA skin infections in mice
Five groups (n = 6/group) of 7–8 week old female, BALB/c mice
were challenged by skin inoculation with MRSA strain USA300.
On Day −1, each mouse was anesthetized with isoﬂurane and the
lesion site was depilated using Nair®. On Day 0 (at −1 h) each mouse
was anesthetized and the lesion site received 7 consecutive appli-
cations and removals of surgical tape (3 M NexcareTM). At time zero,
each animal on the study was  administered a topical administration
of 10 L of the bacterial suspension, delivering a total challenge of
3.56 × 107CFU per mouse. Group 1 received IV saline 4 h before and
48 h after bacterial challenge. Group 2 received daily oral admin-
istration of 12.5 mg/kg Linezolid beginning immediately following
the bacterial challenge and continuing for 4 days following chal-
lenge. Group 3 received 25 mg/kg SGX94 IV 4 h before bacterial
challenge. Group 4 received 25 mg/kg SGX94 IV 4 h before and 48 h
after bacterial challenge, while Group 5 received 100 mg/kg SGX94
by SC administration 4 h before and 48 h after bacterial challenge.
Efﬁcacy of test article to protect the skin from scab formation
was assessed by digital photography at 48 and 96 h post-infection.
A pathologist examined the images in a double-blinded fashion.
Pathologic criteria to assess the skin images macroscopically were
used as follows: Abrasions; Depressed/Glistening surface; Discol-
oration; Exfoliation; Scab formation; Swelling; Ulceration. Severity
grades ranged from 0 (not present) to 4 (marked/severe alter-
ations present). At the completion of the evaluation, the data were
unblinded and the group total and mean group scores were gener-
ated.
1.6.7. P. aeruginosa GI infections in rats
The neutropenic rat model has been described in detail
previously (Opal et al., 2001). Speciﬁc pathogen-free, female,
albino Sprague-Dawley rats (Charles River Laboratories) weighing
150–200 g were administered 10 mg/kg Cefamandole intramuscu-
larly (IM) every 2 days between Days −4 and 10 to disrupt their
gastrointestinal ﬂora. Severe neutropenia was induced by admin-
istration of cyclophosphamide 75 mg/kg IP on Days 0 and 3. P.
aeruginosa immunotype 6, strain 12.4.4 (1 × 106 CFU/mL) was
given by orogastric feedings on Days 0, 2 and 4. Due to the break-
down of the gastrointestinal mucosal barrier, rats developed fever
by Day 5, and began dying of sepsis by Day 7. SGX94 (10 mg/kg IV)
or Saline (IV) was  administered once after the appearance of fever.
In another group of rats, Cefepime was administered on Days 6, 7
and 8 (25 mg/kg IM). Survival was  monitored (N = 8 SGX94, Saline,
N = 4Cefepime). Differences in survival time between groups were
analyzed by Kaplan-Meier survival plots and log-rank testing.
1.6.8. Burkholderia pseudomallei lung infection in mice
The efﬁcacy of SGX94 in treating melioidosis was  assessed in
an acute pneumonic model of infection. Highly susceptible BALB/c
mice were challenged intranasally with 3 × 103CFU (∼3xLD50)
of the virulent strain 1026b of B. pseudomallei under BSL3 con-
tainment. Intranasal infection of the mice results in an acute
disseminated infection with features typical of severe human
melioidosis including extensive abscess formation in the lungs
and dissemination to other organs such as the spleen and liver
(Titball et al., 2008). Terminal illness in the mice is associated with
bacterial proliferation in the lungs. SGX94 (50 mg/kg) or saline
was administered IV 4 h prior to infection and every second day
to Day 8. Sub-optimal Doxycycline (20 mg/kg administered orally
upon infection and daily through day 10) was used as the com-
parator antibiotic given its characterization in mouse models of
melioidosis (Gelhaus et al., 2013) and because a sub-optimal antibi-
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Table  1
Plasma PK parameters for SGX94 in Mouse (CD-1), NHP (Cynomolgus macaques) and Human.
Species Dose Level &
Infusion Time
Maximum
Concentration
Cmax
(ng/mL) ± SD
Time of
Maximum
Concentration
Tmax (min) ± SD
Area under the
Curve AUC 0-t
(h*ng/mL) ± SD
Mean Residence
Time MRT
(min) ± SD
Mouse (male) Day 14 20 mg/kg over ∼1 min; N = 2 23020 3 4498 2.3
60  mg/kg over ∼1 min; N = 3 41220 3 9288 1.8
90  mg/kg over ∼1 min; N = 4 72170 3 17430 1.6
Mouse (female) Day 14 20 mg/kg over ∼1 min; N = 2 8079 3 1696 2.0
60  mg/kg over ∼1 min; N = 3 27130 3 6515 6.5
90  mg/kg over ∼1 min; N = 4 45750 3 10400 1.8
NHP  (male) Day 14 20 mg/kg over ∼2–3 min; N = 3 6650 ± 2519 NR 1328 ± 438 7.8 ± 6.6
80  mg/kg over ∼2–3 min; N = 3 85860 ± 25830 NR 19390 ± 6913 7.8 ± 2.4
160  mg/kg over ∼ 2–3 min; N = 3 205500 ± 33420 NR 45950 ± 9567 7.2 ± 1.2
NHP  (female) Day14 20 mg/kg over ∼2–3 min; N = 3 12400 ± 6411 NR 2412 ± 1231 6.6 ± 1.2
80  mg/kg over ∼2–3 min; N = 3 16870 ± 24750 NR 3361 ± 4709 55 ± 85
160  mg/kg over ∼ 2–3 min; N = 3 178800 ± 132300 NR 36340 ± 26430 6.6 ± 1.2
Human
(males  + females) SAD
0.15 mg/kg over 4 min; N = 6 510 ± 222 4.0 ± 0.0 41 ± 15 5.4 ± 1.2
1.0  mg/kg over 4 min; N = 5 4326 ± 2829 4.8 ± 1.8 323 ± 189 7.2 ± 0.6
2.0  mg/kg over 4 min; N = 6 5873 ± 2096 4.4 ± 0.8 491 ± 87 4.8 ± 1.2
3.0  mg/kg over 4 min; N = 6 14436 ± 6385 4.0 ± 0.0 1043 ± 428 3.6 ± 0.6
5.0  mg/kg over 4 min; N = 6 13636 ± 7838 4.9 ± 1 1152 ± 483 6.0 ± 2.4
8.0  mg/kg over 4 min; N = 6 31039 ± 19372 4.1 ± 0.4 2423 ± 1194 4.2 ± 0.6
Human
(males  + females) MAD,
day 7**
0.5 mg/kg over 4 min; N = 4 1164 ± 592 4.0 ± 0.0 89 ± 14 5.4 ± 0.6
1.5  mg/kg over 4 min; N = 4 5541 ± 3723 4.5 ± 1 388 ± 280 3.6 ± 1.2
3.0  mg/kg over 4 min; N = 4 13407 ± 4427 4.3 ± 0.5 1001 ± 321 3.6 ± 0.6
4.5  mg/kg over 4 min; N = 4 16583 ± 10218 5.0 ± 1.1 1473 ± 677 3.6 ± 0.6
6.5  mg/kg over 4 min; N = 4 31391 ± 6673 4.0 ± 0.0 2108 ± 413 3.0 ± 0.0
Notes: NR = Not Reported; SAD = Single Ascending Dose; MAD  = Multiple Ascending Dose; SD = Standard Deviation; ** PK was  assessed on both days 1 and 7 of the MAD  phase,
with  no signiﬁcant differences (no evidence of bioaccumulation). Day 1 data not shown.
Fig. 1. Broad-spectrum activity of SGX94 against bacterial infections. a) Peritonitis: S. aureus infection in CD-1 mice (n = 8/group). Control and SGX94 (9.5 mg/kg) were
injected IP 4 h later. Bacterial counts were assessed 24 h after infection. Open symbols indicate dead mice. b) Thigh abscess: SGX94 (50 mg/kg) was  administered IV at 24 h
or  4 h before infection of neutropenic male CD-1 mice with MRSA (right thigh). Vancomycin (30 or 100 mg/kg) was given SC at 2 h and 14 h after infection. CFU counts were
determined 26 h post-infection. c) Skin infection: SGX94 (n = 6/gp) was administered IV or SC. Oral linezolid (12.5 mg/kg) was  administered daily after infection with MRSA in
CD-1  mice. A blinded board-certiﬁed pathologist scored the digital images. d) Bacteremia: SGX94 (5 mg/kg) or saline was administered IV 4 h or 24 h after infection of BALB/c
mice  with MRSA via the tail vein (n = 10/group). A single dose of Linezolid (6.25 mg/kg) was administered orally after infection (n = 10). e) Peritonitis: SGX94 (50 mg/kg) or
saline  treatment was administered IV 48 h before MRSA infection of female CF-1 mice (N = 10/group), followed by vancomycin (3 mg/kg) was administered to all animals SC,
1  h and 5 h after infection. f) Melioidosis: Female BALB/c mice (N = 12/group) were infected intranasally with B. pseudomallei. SGX94 (50 mg/kg) or saline was administered
IV  4 h prior to infection and every second day to Day 8. Doxycycline (20 mg/kg) was administered orally upon infection and daily through Day 10. MST  = median survival
time.  N = 12/group. The combination of SGX94 + doxycycline was found to be more effective than the additive combination of each treatment alone (p < 0.0001). g) Sepsis:
Female  Sprague-Dawley rats were infected with oral P. aeruginosa on Days 0, 2 and 4 (n = 8 SGX94, Saline, n = 4Cefepime). With the onset of fever (Day 5), animals received
SGX94  (10 mg/kg IV), Cefepime (40 mg/kg IM on Days 6–8) or saline (IM on Days 6–8). h) Bacteremia: SGX94 (50 mg/kg) or saline was  administered IV 4 h prior to infection
of  BALB/c mice with MRSA via the tail vein (n = 10/group). The animals were monitored for 21 days post-infection.
28 J.R. North et al. / Journal of Biotechnology 226 (2016) 24–34
Fig. 2. Prophylactic and persistent impacts of SGX94 on MRSA bacteremia. a) SGX94 (50 mg/kg) or saline (n = 10/group) was  administered IV to female BALB/c mice 5 days
prior  to infection via the tail vein with MRSA (USA300, 1.9 × 107 CFU). The statistical signiﬁcance of differences in survival were assessed using Kaplan Meier analysis. b)
SGX94  (5 mg/kg) or saline (n = 10/group) was  administered IV at the indicated times to female BALB/c mice prior to or after infection via the tail vein with MRSA (USA300,
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a × 107 CFU). Sub-optimal antibiotic treatment (linezolid, 6.25 mg/kg) was  admini
nce  4 h prior to infection with MRSA (strain USA300, 1.1 × 107 CFU) via the tail v
ound with the 50 mg/kg dose level relative to the saline control, as assessed using 
tic treatment enables any additive impact of IDR therapy to be
ore easily discerned. The log rank Mantel-Cox test was used.
ynergy was also assessed, evaluating the treatment of SGX94
lus doxycycline against treatment with either SGX94 or doxy-
ycline alone using one-way ANOVA with planned comparison
contrast/estimate statements). Duration to event was  treated as a
esponse variable and treatment with 3 levels as independent vari-
ble. The comparison tested Mean(SGX94) + Mean (Doxy) = Mean
Combo).
.6.9. Pulmonary inﬂammation in mice
SGX94 or saline was administered IV to 6–7 week old female
ALB/c mice at 50 mg/kg (N = 10/group). Pulmonary inﬂamma-
ion was induced by intranasal administration of LPS (Sigma) at
00 ng/mouse 1 h after SGX94 injection. Mice were euthanized 4 h
fter the LPS administration and bronchoalveolar lavage was per-
ormed. The non-cellular portion of the lavage ﬂuid was analyzed
or TNF-, IL-1, IL-6 and IL-1ra levels. Other than IL-1ra, none of
he other parameters were signiﬁcantly altered by SGX94 treat-
ent at the selected timepoints. Statistical analysis compared the
GX94 treated group and the vehicle treated control groups with a
ne-tailed Student’s t-test using GraphPad Prism v5.03.
.7. Neutropenic mice: leukocyte recovery and MRSA thigh
nfections
CD-1 mice were rendered neutropenic by IP injection of
50 mg/kg and 50 (Supplemental Fig. 2) or 100 mg/kg (Fig. 1b) of
yclophosphamide at 96 and 24 h prior to the experiment, respec-
ively. These treatment regimens have been shown to induce severe
eutropenia (≤10 neutrophils/mm3 blood) for at least 72 h (Zuluaga
t al., 2006). To evaluate the impact of SGX94 on recovery of cir-
ulating leukocytes, female mice were used (Supplementary Fig.
2). In a separate experiment, neutropenic male mice (n = 10 per
roup) were treated IV with 50 mg/kg SGX94 or saline 4 or 24 h
rior to IM infection with MRSA (1.24 × 105 CFU/mouse) in 1 thigh.
n other groups, vancomycin (30 mg/kg or 100 mg/kg, SC) was
dministered at 2 and 14 h after the infection. For concomitant
ancomycin and SGX94 treatment, mice were given 30 mg/kg of
ancomycin. Muscle of the infected thigh was removed 26 h after
nfection and homogenized. Homogenate supernatants were plated
or CFU determination (Fig. 1b).
.8. Cynomolgus monkeys
One male and 1 female cynomolgus monkey (Macaca fascicu-
aris) were obtained from Worldwide Primates Inc. At the start
f treatment, both animals were young adults (approximately 3
ears old weighing 3.2 kg [male] and 2.4 kg [female]). SGX94 was
dministered to each monkey at dose levels of 3, 10, 30, 90, 180, orally immediately after infection. c) SGX94 (IV) or saline (IV) was administered
to female nu/nu mice. Statistically signiﬁcant (p ≤ 0.05) increases in survival were
 Meier analysis.
and then 240 mg/kg as single slow IV injections (over at least
60 s) on 6 separate days, with a washout period of at least 3 days
between injections. Blood samples were collected on K3EDTA from
all animals following the ﬁrst (3 mg/kg), third (30 mg/kg) and sixth
(240 mg/kg) dosing occasions at 8 timepoints (3, 15, 30 min, 1, 2,
6, 10, 24 h post-dose). Samples were centrifuged at 1500g RCF for
10 min  to obtain plasma and immediately frozen at −70 ◦C.
1.9. Phase 1 clinical study
A phase 1, single centre, placebo-controlled, randomized,
double-blind, single- and multiple-ascending dose (SAD; MAD)
study has been completed to evaluate the safety, tolerability and
PK of SGX94 injectable solution in normal healthy volunteers. All
subjects signed informed consent after a full explanation of the
potential risks. A total of 54 subjects (20 females and 34 males),
age range 18–55 years, were enrolled into the SAD phase and a
total of 30 subjects (5 females and 25 males), age range 18–55 years,
were enrolled into the MAD  phase. In the SAD phase, a total of 6
dose levels of SGX94 (0.15, 1, 2, 3, 5 and 8 mg/kg) were evaluated.
Subjects were randomized within each of Cohorts 1–6 to receive a
single IV infusion of SGX94 at a single dose level, or placebo. Cohorts
were dosed sequentially with ascending doses of SGX94. Cohorts 1
and 2 consisted of 11 subjects (n = 8 SGX94, n = 3 Placebo) includ-
ing 3 sentinels who  received 60 min  infusions (n = 2 SGX94, n = 1
Placebo) and 8 subjects who received 4 min  infusions (n = 6 SGX94,
n = 2 Placebo). Cohorts 3–6 consisted of 8 subjects (n = 6 SGX94, n = 2
Placebo) receiving 4 min  infusions.
In the MAD  phase, a total of 5 dose levels (0.5, 1.5, 3, 4.5
and 6.5 mg/kg daily) were evaluated, each administered daily over
7 days. Subjects were randomized within each of Cohorts 7–11 to
receive daily IV 4 min  infusions of SGX94 (n = 4) or placebo (n = 2).
Blood samples were taken at predetermined times from all
subjects in both phases of the study for both PK (Table 1) and
pharmacodynamic (PD) analysis. In the SAD phase and on days 1
and 7 of the MAD  phase, blood samples for PK analyses were col-
lected within 1 h prior to infusion, 4 (immediately after infusion),
6, 9, 15, 20, 30, and 45 min  and at 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and
24 h after the start of infusion. Plasma was prepared (K3EDTA) and
SGX94 concentrations were determined by LC–MS/MS using GLP
validated methods (quantitation limit 0.1 ng/mL). PK analyses were
performed using non-compartmental methods.
Blood samples for the PD analyses reported here were drawn at
1 h after SGX94 or saline infusion (4 min  infusion only). To deter-
mine the PD impact of SGX94, cytokine and chemokine levels were
quantiﬁed after 4 h of in vitro stimulation of whole blood with
LPS (E. coli). Samples were subsequently analyzed by Rules Based
Medicine, Inc. utilizing their standard protocols. The following
panel of cytokine and chemokine analytes were quantiﬁed: IL-1;
IL-1; IL-6; IL-1ra; TNF; TNF RII; MCP-1; MIP-1 (CCL3); MIP-1
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CCL4); and RANTES. To increase sample sizes for comparison pur-
oses, data from the SAD and Day 1 of the MAD  was  combined into
 dose groups, “low dose” from 0.15–2.0 mg/kg (n = 26) and a “high
ose” from 3.0–8.0 mg/kg (n = 30), resulting in roughly equal sam-
le numbers. Similarly, results from SAD and Day 1 MAD  subjects
eceiving placebo were combined (n = 22). As expected, given the
linical literature on cytokines and chemokines, initial data analysis
evealed a high inter-individual variability in quantitative in vitro
esponses to LPS. The analyte level at each timepoint for each indi-
idual was therefore divided by the pre-dose analyte level for that
ndividual, yielding a self-normalized activity ratio (AR) for each
nalyte and each individual at every timepoint.
. Results
.1. IDRs enhance clearance of bacterial infection without
actericidal activity and are complementary to antibiotic action
SGX94 enhanced bacterial clearance and/or survival in murine
nfection models with Gram-positive antibiotic sensitive S. aureus
Fig. 1a) and antibiotic resistant methicillin-resistant S. aureus
MRSA; Fig. 1b–e, h) as well as Gram-negative P. aeruginosa (Fig. 1 g)
nd antibiotic resistant B. pseudomallei (Fig. 1f). In addition to this
road spectrum protection, SGX94 is also systemically active, since
ot only SC administration for skin infections (Fig. 1c), IP admin-
stration for peritoneal infection (Fig. 1a) and IM administration
or thigh infections (data not shown) but also systemic administra-
ion is protective at a variety of anatomical locations including skin
Fig. 1c), tissue (Fig. 1b and 1e), blood (Fig. 1d, h, Fig. 2), gastroin-
estinal induced septicemia (Fig. 1g), and lung induced septicemia
Fig. 1f). SGX94 treatment, whether administered prophylactically
Fig. 1b–c, 1e, 1 h; Fig. 2a) or therapeutically (up to 5 days after infec-
ion − Fig. 1a,d,g), is effective when given alone. Dose response
tudies in the MRSA bacteremia models suggested that efﬁcacy
ould be demonstrated at doses between 5 and 50 mg/kg, with
obust results obtained between 25 and 50 mg/kg IV (Supplemen-
ary Table 1). Other infection studies commonly used dose levels
etween 5 and 50 mg/kg for IV administration, while SC and IM
njections generally utilized higher concentrations on the assump-
ion that systemic delivery was required. No dose response studies
ith non-IV routes of administration have been conducted.
By contrast, when SGX94 was evaluated for direct antimicro-
ial activity using standard minimum inhibitory concentration
MIC) assays with S. aureus and E. coli it showed no signiﬁcant
ctivity against either organism. SGX94 was tested in 2 sepa-
ate experiments for each bacterial strain in serial 1:2 dilutions
rom 200 M to 6.25 M while erythromycin (S. aureus assay)
nd Polymixin B (E. coli assay) were tested in serial 1:2 dilu-
ions from 200 g/mL to 6.24 g/mL. SGX94 showed no activity
MIC > 200 M = 111 g/mL); by comparison, erythromycin and
olymycin B were both active at <3.125 g/mL. Similarly, neither
acteriostatic nor bactericidal activity was detected with SGX94
reatment of either S. aureus or E. coli using a sensitive prolifera-
ion assay (Supplementary Table 2). These data indicate that the
nti-infective impact of IDRs depends upon interaction with host
efense systems. The observed complementarity between SGX94
reatment and antibiotic action (Fig. 1b,e,f) is consistent with this
odel.
The broad-spectrum applicability of the IDRs is particularly
oteworthy in view of the varying biological niches that each
f these bacteria occupy, ranging from primarily extracellular
athogens (S. aureus)  to facultative intracellular pathogens (B. pseu-
omallei, a category B biothreat agent). This broad scope of action
uggests that IDRs function as upstream modulators of multiplehnology 226 (2016) 24–34 29
pathways simultaneously. To explore this concept in more detail,
the PK and PD of SGX94 were further investigated.
2.2. IDRs have a short pharmacokinetic half-life and a prolonged
pharmacodynamic impact
Studies of SGX94 in cell cultures, plasma and blood indicate a
rapid rate of degradation unless stabilized by the application of
protease inhibitors and/or rapid cooling. Thus, any SGX94 activity
must not be dependent on its enduring extracellular presence.
The PK proﬁle of SGX94 has been characterized in mouse, non-
human primate and humans. As would be expected for a 5-amino
acid peptide composed entirely of l-amino acids, the PK half-
life is very short (minutes), is consistent between species and
shows no evidence of bioaccumulation after multiple daily dosing
(Table 1). Moreover, since short peptides are primarily degraded
by blood and tissue resident proteases and do not depend on liver
or kidney metabolism, IDRs would not be expected to interfere
with the pharmacokinetics of other drugs, including potentially
complementary drugs such as antibiotics. QWBA data showed
drug-derived radioactivity to be rapidly and widely distributed,
with signiﬁcant accumulation in stomach, large intestine, small
intestine, adrenal gland, kidney, pancreas, liver, lung and salivary
glands (data not shown). Additional animals from the same study
were analyzed for blood metabolism and by 5 min  post-dose the
major analyte in blood was  a metabolite of SGX94, consistent with
the rapid mean residence time (Table 1). Consistent with micro-
somal stability studies, the major metabolites resulted from the
removal of the N-terminal amino acids, suggesting the major degra-
dation pathway was driven by N-terminal peptidases both in vivo
and in vitro. Concentrations in all tissues were lower than those in
blood at 2 min  and in most tissues at 5 min  post-dose. Radioactive
signals after 5 min  post-dose likely represented amino acid recy-
cling of the labelled metabolite, given the metabolite results cited
above. Concentrations in the central nervous system (CNS), bone,
white adipose and eye lens were the lowest of all tissues and were
not observed within 2 min  of dosing, indicating low penetration of
SGX94 into these tissues.
All studies to date (stability in blood, plasma and cell culture,
in vivo pharmacokinetics and metabolite proﬁling) support a rapid
extracellular degradation of SGX94. The in vitro activity of IDRs on
selective p62 complex formation (e.g., increased p62:RIP-1 com-
plex formation but not p62:PKCz) has been demonstrated within
30 min  (Yu et al., 2009). Thus, while the “on-rate” of SGX94 into the
cell and on the target is apparently rapid (within 30 min), the “off-
rate” has not been determined and the persistence of binding of
SGX94 to the target protein is not known. Competitive assays have
demonstrated that SGX94 can be competed off and that the bind-
ing is not covalent (Yu et al., 2009) suggesting that some kinetic
on-off behaviour would be expected and would expose SGX94 to
intracellular peptidase action.
The PD proﬁle of SGX94 has been evaluated in a number of con-
texts. As shown in Fig. 2a, prophylactic administration of SGX94 up
to 5 days prior to infection enhances survival. Similar results are
seen in peritoneal infection models with administration up to 48 h
prior to infection (Fig. 1e). Moreover the impact of SGX94 is endur-
ing (Fig. 1 h). The impact of SGX94 on very severe infection was
explored by administration of additional doses of SGX94 between
8 and 76 h post-dose (Fig. 2b). Second doses administered within
8 and 28 h of the ﬁrst dose did not increase survival, while doses
administered between 52 and 76 h after the ﬁrst dose were addi-
tively effective. In light of the short half-life of SGX94, these data
suggest that a persistent change in cell state is triggered by IDR
treatment.
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.3. IDRs alter cellular recruitment and are effective in
mmune-deﬁcient animals
Early work suggested that IDR action was driven by myeloid
erived cells, as it is abrogated by treatment with clodronate (Scott
t al., 2007). In contrast, however, SGX94 was shown to be active in
nimals rendered neutropenic and leukopenic by the administra-
ion of cyclophosphamide (Fig. 1b,g), with an activity proﬁle similar
o that seen in immunocompetent animals (Fig. 1a,c–f, Fig. 2a–b).
GX94 was also active in protection of T-cell deﬁcient nu/nu mice
Fig. 2c), while Scott et al. (2007) reported that IDR-1, a related pep-
ide, was active against S. aureus peritoneal infection in Rag-1−/−
nock-out mice. Moreover, SGX94 does not impact the recovery
roﬁle of circulating leukocytes following leukopenia induced by
yclophosphamide (Supplementary Fig. S2). These results suggest
hat the main actor in response to IDRs is not a circulating leuko-
yte; although, a direct study of NK cells has not been undertaken.
Evaluations of cytokine expression and cellular recruitment to
he site of a peritoneal infection revealed that the chemokines
ANTES (CCL-5) and IP-10 (CXCL-10) were elevated at 3 h
ost-infection in SGX94-treated mice (Fig. 3a), consistent with
he observed increase in recruitment of macrophages (but not
eutrophils) to the site of infection (Fig. 3b). Decreased pro-
nﬂammatory signaling (TNF) was observed in the same system,
ost markedly at later timepoints (Fig. 3c). The possibility was
herefore considered that IDRs might alter the maturation of mono-
ytes into M1  or M2  macrophages, as has been reported for other
ationic peptides such as lactoferrin (van der Does et al., 2010a) and
L-37 (van der Does et al., 2010b). Accordingly, CD14+ mononuclear
ells were differentiated to M1-  or M2-type macrophages by GM-
SF or M-CSF exposure, respectively, in the presence and absence
f 30 min  pre-treatment with SGX94. After 5 days of differentia-
ion, the behaviour of the macrophages was assessed by stimulating
hem with endotoxin (LPS). The ability of the growth factors to drive
ifferentiation was not impacted by SGX94, although the degree
f inﬂammatory response of the M2  macrophages was  somewhat
odulated with small statistically signiﬁcant decreases in TNF
nd IFN (Supplementary Fig. S3).
.4. IDR effects on signaling by tissue-resident cells
It was postulated that the key responding population may  be
issue-resident and studies were undertaken with splenocytes,
n immune active and accessible organ containing a heteroge-
eous population of cell types. Studies to detect any impact of
GX94 exposure on the responses of mouse splenocytes directly
timulated with LPS, LPS ± IFN, CpG, Flagellin, PGN, poly(I:C),
r TNF did not reveal any robust or consistent changes in
ytokine/chemokine signaling (Fig. 4 see purple lines). However,
ince monocytes/macrophages have been shown to be integral
o the protective IDR effect (Scott et al., 2007) (Fig. 3b), in vitro
upernatant transfer experiments were also undertaken, utiliz-
ng cell culture supernatants from mouse splenocytes stimulated
ith LPS in the presence or absence of SGX94 (Fig. 4a). Condi-
ioned media from these splenocyte cultures were used to culture
esponder cells from a mouse macrophage cell line (RAW264.7),
hich lead to statistically signiﬁcant and reproducible alterations
n macrophage responsiveness (Fig. 4). Conditioned medium from
ach mouse splenocyte preparation was also measured directly for
ytokine levels, conﬁrming that the changes after RAW cell incuba-
ion were not due to direct differences in the given analytes in the
riginal conditioned media (Supplemental Fig. 4a). Similarly, RAW
ells are not consistently responsive to SGX94 with LPS stimulation
Supplemental Fig. 4b). Viability studies were also undertaken and
onﬁrmed that cellular viability did not vary across the treatment
onditions (Fig. 4c). Identical results were obtained with spleno-hnology 226 (2016) 24–34
cytes from BALB/c mice that are Th2 and M2  biased (Locksley et al.,
1987; Gessner et al., 1993; Sellers et al., 2012) (Fig. 4b) and C57BL/6
mice that are Th1 and M1  biased (Locksley et al., 1987; Gessner
et al., 1993; Sellers et al., 2012) (Fig. 4c), indicating that the IDR
response is not dependent on either T-cell or macrophage phe-
notype bias. This was in agreement with the efﬁcacy observed in
various mouse strains (Fig. 1, Fig. 2) (Scott et al., 2007).
While IDRs have not previously been observed to bind endotoxin
directly, it remained possible that inactivation of the nega-
tively charged LPS by the cationic IDRs caused the reductions
in cytokine/chemokine levels. The time separation and mixing
between endotoxin and SGX94 additions and the elapsed time
between SGX94 addition and application of the conditioned media
to RAW cells suggested this was  not the case. Attempts to remove
potential LPS impact by polymyxin B addition were inconclu-
sive because the residual LPS is necessary to stimulate the RAW
cell preparation. Therefore, IDR analogs were used as indirect
controls to assess the potential impact of direct IDR  binding to
endotoxin. These included an analog with a single d-amino acid
substitution (SGX972) that does not bind to the protein p62 but
maintains the same net charge, and a stronger p62 binder with
more structural differences (SGX1236). The expected SGX94 effect
was observed, while the stronger binder showed a more signiﬁ-
cant impact and the non-binder, SGX972, had no impact (Fig. 4d).
Given the charge and sequence similarity between SGX94 and the
non-binder SGX972, these results support the interpretation that
the differences in cytokine responses are not attributable to direct
interaction between the IDRs and LPS but correlate with binding to
the p62 target protein.
2.5. SGX94 is anti-inﬂammatory and consistent between species
Upon stimulation of whole animals or mixed cell popula-
tions in vitro with LPS, SGX94 modulated TNF, IL-6 and other
inﬂammatory cytokine responses (Fig. 3a,c Fig. 4a–b). The effect
involved multiple cytokines and chemokines, tended to be sub-
tle (i.e., approximately 30–50% suppression) and was associated
with coordinated impact on anti-inﬂammatory cytokines. Con-
sistent with these data, in a Phase 1 human study, where blood
taken from humans after SGX94 administration was challenged ex
vivo with LPS, TNF responses were found to decrease while anti-
inﬂammatory TNF RII responses increased, resulting in an increase
in the ratio of TNF RII/TNF (Fig. 5a). Similarly, IL-1 response was
found to decrease while IL1-ra increased, resulting in an increase
in the IL-1ra/IL-1 ratio (Fig. 5a). While the TNF RII, TNF, IL-1ra,
IL-1 and IL-1 have minimally overlapping 95% conﬁdence inter-
vals (p-values could not be determined since the analysis method
was not deﬁned a priori), other analytes including IL-6, MCP-1,
MIP-1,  MIP-1 and RANTES were highly overlapping (Supplemen-
tary Fig. S5). In addition, while non-overlapping responses were
observed for the low-dose group, the high dose group did not
demonstrate similar responses and overlapped the placebo pop-
ulation very closely (data not shown), suggesting a suppression of
response at higher dose levels. Note that the high dose levels cor-
respond to mouse doses of 40–96 mg/kg, while efﬁcacy testing has
generally been limited to no higher than 50 mg/kg in the mouse.
IL-1ra was also found to be responsive in healthy non-human
primates (Fig. 5b); note however that the study evaluated increas-
ing dose in the same two  individuals. It is unclear if the lack of
dose response represents an exhaustion of the IL-1ra response over
time or a true reduction in response at higher dose levels. Either
explanation would be reasonable given that immunomodulatory
compounds are generally known to have non-linear dose response
relationships. IL-1ra levels were also observed to change in mice
(Fig. 5c) after an inﬂammatory stimulus. Despite changing con-
ditions, IL-1ra levels were found to respond in all species tested,
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Fig. 3. Cytokines and cell migration during S. aureus peritoneal infection: a) SGX94 (30 mg/kg) was administered IP to female CD-1 mice (n = 8/group). 24 h later an inoculum
of  S. aureus (Catalog No. 25923, ATCC, ∼0.5–1 × 108 CFU) with 5% mucin was  injected IP. Mice were sacriﬁced 3 h after infection and peritoneal lavage ﬂuid was assessed
for  cytokine levels. b) Female CD-1 mice were injected IP with S. aureus (Catalog No. 25923, ATCC, 8.4 × 107 CFU) with 5% mucin. Saline (n = 8/group) or SGX94 (15 mg/kg;
n  = 12/group) was  administered IP or IV 4 h after infection. Mice were sacriﬁced 24 h after infection and peritoneal lavage ﬂuid was assessed for macrophage and neutrophil
numbers. Only 1/8 animals survived in the control saline IV group, whereas 5/12 and 9/12 animals survived in the SGX94-treated IV and IP groups, respectively. Each data point
represents a single animal and the bars represent average cell counts for each treatment group. c) SGX94 (30 mg/kg) was administered IP to female CD-1 mice (n = 8/group)
24  h prior to an IP inoculation with a low dose of S. aureus (Catalog No. 25923, ATCC, 1.8 × 106 CFU) with 5% mucin. Mice were sacriﬁced 24 h after infection and peritoneal
lavage  ﬂuid was  assessed for TNF levels. A t-test was performed comparing the SGX94 and saline groups, assuming that any data point with a value less than the detection
limit  of the assay (dotted line) was 0.
Fig. 4. Splenocyte supernatant transfer study: a) Schematic of study design b and c) BALB/c (b) and C57BL/6 (c) splenocytes were pre-incubated with control (black circles)
or  SGX94 (blue square), 200 M,  as described in the methods and the supernatant medium was  applied to the RAW264.7 cells. M1 through M5 indicate splenocyte cultures
from  individual mice. Purple symbols and lines on the graphs indicate the “input” levels of the cytokines from the splenocyte conditioned media that was applied to the
RAW  cells. Each symbol represents one well of the RAW cell culture. d) C57BL/6 splenocytes were pre-incubated with each IDR, 200 M,  as described in the methods and the
pooled supernatant medium was applied to the RAW264.7 cells. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version
of  this article.)
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Fig. 5. Consistent cytokine proﬁles across species. a) In a Phase 1 study in healthy human volunteers blood samples were obtained 1 h post-treatment from the placebo
(n  = 22) and SGX94-treated populations (Low dose: 0.15–2.0 mg/kg, n = 26; High dose: 3.0–8 mg/kg, n = 30). Blood samples were immediately incubated with LPS (E. coli) for
4  h and analyzed for cytokine/chemokine responses. Placebo group data and combined data from low dose groups of the SAD and MAD data sets are represented in Fig. 5a
as  the ratios of IL-1ra/IL-1 and of TNF RII/TNF responses, respectively. Solid lines with symbols in Fig. 5a indicate the mean responses of the placebo (black triangles) and
low  dose (blue circles) populations, dashed black lines and solid blue lines without symbols indicate the respective 95% Conﬁdence Intervals (CI) for the placebo and low
dose  populations, respectively. The 95% CI for the SGX94 treated population is also shaded to emphasize areas of minimal overlap between the 2 populations. Boxes indicate
non-  or minimally-overlapping 95% CI between the 2 populations. b) SGX94 was administered to one male (1001A) and one female (1501A) cynomolgus monkey at the
indicated doses and blood samples were collected up to 24 h post-dose. The levels of IL-1ra in the plasma are shown. c) 50 mg/kg SGX94 or saline was administered IV to
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o  the web version of this article.)
ndicating a consistency in the biological response to SGX94 across
pecies with highly conserved innate immune systems.
. Discussion
The rise of emerging and antibiotic resistant infectious disease
oses increasing challenges in both the developing and devel-
ped world. New antibiotic classes are difﬁcult to ﬁnd and face
he same threat of rapidly emergent resistance. A complementary
pproach to infectious disease would be to further harness the
nnate immune system. Early attempts to direct innate defenses
ocused on altering speciﬁc inputs or outputs to the system. Com-
ounds like TLR agonists work well as prophylactic treatment for
nfection, however, their function in also triggering inﬂammation
ake them less useful in a therapeutic setting. Similarly, thera-
ies targeted at the inﬂammatory outputs of the innate immune
ystem also suppress the infection-ﬁghting aspects of the innate
mmune system (Cantini et al., 2014, 2015; Fleischmann et al.,nasally in a volume of 30 L. Four hours after LPS administration, bronchoalveolar
terpretation of the references to colour in this ﬁgure legend, the reader is referred
2003). Modulation of the interplay between infection-ﬁghting and
inﬂammatory signaling may  require an alternative approach − i.e.,
acting on the intracellular signaling pathways that direct the subse-
quent signaling. IDRs provide a potential tool to accomplish this by
targeting the intracellular protein, sequestosome-1 (p62) (Yu et al.,
2009), which functions as an adaptor protein downstream of many
innate defense receptors (Into et al., 2010; Park et al., 2013; Kim
and Ozato, 2009; van der Vaart et al., 2014).
In studies reported here and those reported previously (Scott
et al., 2007), IDRs − while possessing no direct anti-bacterial
activity − show broad-spectrum activity against infections with
bacteria which occupy differing biological niches − from the pri-
marily extracellular pathogens like S. aureus to the facultative
intracellular bacteria like B. pseudomallei. These extensive in vivo
evaluations indicate that the IDR SGX94 fulﬁlls the original promise
of IDRs − being agnostic to the speciﬁc bacterial threat, effec-
tive when administered prophylactically or therapeutically, and
complementary to antibiotics. Because IDRs are agnostic, they can
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e administered before the speciﬁc causative infectious agent is
nown. Since IDRs are unlikely to engender resistance, they can
lso be given to at-risk patients without fear of increasing antibiotic
esistance. The use of IDRs may  also be antibiotic-sparing, poten-
ially reducing the generation of antibiotic resistance.
In distinct contrast to their rapid degradation and clearance from
lood, cells and in cell culture, the pharmacodynamic action of
GX94 is prolonged both in vitro and in vivo, while its therapeutic
mpact is rapid (Figs. 1 and 2). These data suggest that SGX94 trig-
ers an immediate response in the innate immune system which
s then sustained in the absence of continued extracellular pres-
nce of SGX94. This implies that the IDR effect is mediated on the
ellular level by altering the “cell state” of subpopulations of cells
as yet uncharacterised). This interpretation is supported by the
xhaustion of the IDR response − such that re-administration of
GX94 within a 24–48 h window has no discernible additive bene-
t (Fig. 2b). Following this logic, it would appear that the cell state
esponsive to IDR action is renewed on an approximately 48–72 h
ycle.
The data reported here show that SGX94, like IDR-1 (Scott
t al., 2007), is effective despite immune suppression, includ-
ng severe leukopenia. The innate immune system is composed
f both circulating and tissue-resident cells and is particularly
ctive at all anatomical barriers between the host and its envi-
onment − including in the lung, skin and gastrointestinal tract
Hackett, 2003; Janeway, 1989). IDR activity has been shown to be
ependent on myeloid cell action (Scott et al., 2007) and it was
nitially postulated that IDRs were inﬂuencing either the recov-
ry of cells from leukopenia or the maturation of monocytes into
1  or M2 phenotypic macrophages. Both of these hypotheses
ere found to be incorrect. Given the complex interplay of the
nnate immune system, investigations were then focused on pri-
ary mixed-cell cultures, speciﬁcally splenocyte cultures. While
he impact of IDRs directly on the splenocyte response to innate
mmune stimuli was minimal and inconsistent within the scope
f typical immune responses (i.e., cytokine/chemokine release),
he conditioned media from IDR-treated, LPS-stimulated spleno-
ytes had a signiﬁcant and consistent effect when incubated with
 mouse macrophage cell line. This impact was sustained indepen-
ent of the source of the splenocytes from either BALB/c (Th2 and
2 biased) or C57BL/6 (Th1 and M1  biased) mice. The activity of
DR peptide analogs was correlated with their ability to bind the tar-
et protein, p62. These results clearly establish myeloid cells as the
econdary mediators of IDR action. The signaling moiety involved
n signaling to the macrophages, and the primary responding cell
opulation(s) in the splenocytes, are still under investigation.
The responses of canonical inﬂammatory cytokines to IDR
reatment constitute a tertiary response and are found to be
ontext-dependent, broad-spectrum and fractional, unlike anti-
nﬂammatory agents directed at speciﬁc innate immune outputs
uch as TNF or IL-1 that obliterate signaling (Cantini et al., 2014,
015; Fleischmann et al., 2003). Imbalances between IL-1 and IL-
ra have been reported to play an important predisposing role in
cute and chronic inﬂammatory diseases (Arend and Gabay, 2000;
rend and Guthridge, 2000) and, similarly, the relative proportions
f TNF to its soluble receptors TNF RI and TNF RII have proved
o be important in a number of clinical conditions (van Deuren,
994; Feldmann et al., 1996; Rooney et al., 2000). The increase in
he ratio of IL-1ra/IL-1 responses and in the ratio of TNF RII/TNF
esponses following SGX94 treatment observed here (Fig. 5a) sug-
est a beneﬁcial down-modulation of inﬂammatory signals coupled
ith an up-modulation of anti-inﬂammatory signals. Consistent
ecreases in inﬂammatory cytokines and coordinated increases in
nti-inﬂammatory cytokines have been demonstrated in mouse,
on-human primate and human responses to SGX94 exposure.
his modulation of inﬂammatory responses is also associated withhnology 226 (2016) 24–34 33
improved tissue healing (Fig. 1c) and suggests that IDRs may  also
function downstream of not only pathogen associated molecular
patterns (PAMPs) (Janeway, 1989) such as LPS but also down-
stream of damage associated molecular patterns (DAMPs) (Seong
and Matzinger, 2004).
IDRs offer clinically important advantages for improved treat-
ment of antibiotic resistant and emerging infectious disease. The
evaluation of the mechanism of action of IDRs has also demon-
strated the importance of tissue resident cells. The therapeutic
ability to target the tissue resident cells in this context has not
been previously demonstrated and suggests that therapies directed
at these cells of the innate immune system may be particularly
fruitful.
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